Drug
Masitinib clinical trials
Also written AB1010.
- studies test it
- 37
- open now
- 4
- in phase 3
- 23
- first study started
- 2004
Keep track of what changes. Save the masitinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
- AB1010
- 27
Studies by the year they started
37 studies that test it; most in 2011 (5)
| Year | Studies |
|---|---|
| 2004 | 2 |
| 2005 | 4 |
| 2006 | 2 |
| 2007 | 2 |
| 2008 | 3 |
| 2009 | 1 |
| 2011 | 5 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 4 |
| 2015 | 2 |
| 2016 | 1 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 2 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 18
- Phase 3
- 23
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 37 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses masitinib is read from its arms, and is right about nine times in ten.
Testing it · 37
- Masitinib in Patients With Mild Alzheimer's DiseaseNot yet recruitingPhase 3AB ScienceNCT05564169Written as Masitinib (4.5)
- Efficacy and Safety of Masitinib in Combination With SoC Versus Placebo in the Treatment of ALS PatientsNot yet recruitingPhase 3AB ScienceNCT07174492Written as Masitinib 4.5 mg/kg/day
- Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS PatientsRecruitingPhase 3AB ScienceNCT03127267Written as Masitinib (6.0)
- Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic TreatmentRecruitingPhase 3AB ScienceNCT04333108Written as Masitinib
- Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple SclerosisSuspendedPhase 3AB ScienceNCT05441488Written as Masitinib (4.5)
- Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate CancerCompletedPhase 3AB ScienceNCT03761225Written as Masitinib
- Masitinib in Combination With Riluzole for the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)CompletedPhase 2/3AB ScienceNCT02588677Written as Masitinib (4.5)
- Masitinib in Patients With Mild to Moderate Alzheimer's DiseaseCompletedPhase 3AB ScienceNCT01872598Written as Masitinib
- Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19Status unknownPhase 2AB ScienceNCT04622865Written as Masitinib
- Masitinib for the Treatment of Severe Mast Cell Activation SyndromeStatus unknownPhase 2AB ScienceNCT05449444Written as Masitinib 4.5 mg/kg/day
- Masitinib in Patients With Symptomatic Mild to Moderate COVID-19Status unknownPhase 2AB ScienceNCT05047783Written as Masitinib Mesylate
- Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)TerminatedPhase 3AB ScienceNCT00812240Written as Masitinib
- Masitinib in Treatment of Patients With Severe Persistent Asthma Treated With Oral CorticosteroidsCompletedPhase 3AB ScienceNCT01449162Written as Masitinib
- Masitinib in the Treatment of Patients With Severe Uncontrolled Asthma and Elevated Eosinophil LevelsCompletedPhase 3AB ScienceNCT03771040Written as Masitinib
- Masitinib Plus Gemcitabine in Pancreatic CancerCompletedPhase 3AB ScienceNCT03766295Written as Masitinib
- Masitinib in Combination With FOLFIRI in Third or Fourth Line of Treatment of Patients With Metastatic Colorectal CancerCompletedPhase 2/3AB ScienceNCT03556956Written as Masitinib
- Masitinib in Combination With Gemcitabine in Advanced/Metastatic Epithelial Ovarian Cancer PatientsCompletedPhase 2/3AB ScienceNCT02490488Written as Masitinib
- Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With ImatinibCompletedPhase 3AB ScienceNCT01694277Written as Masitinib
- Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of c-KitTerminatedPhase 3AB ScienceNCT01280565Written as Masitinib
- Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple SclerosisCompletedPhase 3AB ScienceNCT01433497Written as Masitinib
Codes
What other systems call masitinib · ClinicalTrials.gg INT005230
- MeSH (NLM) C526575masitinibOne source NLM
- UNII (FDA) M59NC4E26PMASITINIBConfirmed FDA, NLM, Wikidata
- Wikidata Q1907109masitinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C79910MasitinibOne source FDA
- DrugBank DB11526One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C526575 | masitinib | One source NLM |
| UNII (FDA) | M59NC4E26P | MASITINIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q1907109 | masitinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C79910 | Masitinib | One source FDA |
| DrugBank | DB11526 | — | One source Wikidata |
Also registered as masitinib mesylate (UNII ZK89EG3A18).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.